PCIDB

KNApSAcK Metabolite C00001502

Metabolite

KNApSAcK Entry

id C00001502
Name Hypoxanthine
CAS RN 68-94-0
Standard InChI InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
Standard InChI (Main Layer) InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)

Cluster

Phytochemical cluster No. 12
KCF-S cluster No. 3820

Link

ChEMBL

By standard InChI CHEMBL1427
By standard InChI Main Layer CHEMBL1427

KEGG

By LinkDB C00262

CTD

By CAS RN D019271

Species

Summary

Plant class

class name count

Family

family name count

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom

Human Protein / Gene in interaction

2 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P00492 Hypoxanthine-guanine phosphoribosyltransferase Enzyme CHEMBL1427 CHEMBL909307 (1) CHEMBL853907 (1)
2 / 1
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL1427 CHEMBL1614458 (1)
0 / 0

CTD interaction (11)

compound gene gene name gene description interaction interaction type form reference
pmid
D019271 248 ALPI
IAP
alkaline phosphatase, intestinal (EC:3.1.3.1) Hypoxanthine inhibits the reaction [Methotrexate results in increased activity of ALPI protein] decreases reaction
/ increases activity
protein 16598758
D019271 581 BAX
BCL2L4
BCL2-associated X protein [Mycophenolic Acid co-treated with Hypoxanthine] results in increased expression of BAX protein affects cotreatment
/ increases expression
protein 21396949
D019271 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 21396949
D019271 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in increased expression of BCL2 protein affects cotreatment
/ increases expression
protein 21396949
D019271 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Mycophenolic Acid co-treated with Hypoxanthine] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 21396949
D019271 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 21396949
D019271 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Mycophenolic Acid co-treated with Hypoxanthine] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 21396949
D019271 4548 MTR
HMAG
MS
cblG
5-methyltetrahydrofolate-homocysteine methyltransferase (EC:2.1.1.13) [Thymidine co-treated with Hypoxanthine co-treated with 5,6,7,8-tetrahydrofolic acid] inhibits the reaction [Methotrexate results in decreased expression of MTR protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 16598758
D019271 4548 MTR
HMAG
MS
cblG
5-methyltetrahydrofolate-homocysteine methyltransferase (EC:2.1.1.13) [Thymidine co-treated with Hypoxanthine] inhibits the reaction [Methotrexate results in decreased expression of MTR protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 16598758
D019271 7498 XDH
XO
XOR
xanthine dehydrogenase (EC:1.17.1.4 1.17.3.2) [[Oxygen deficiency results in increased abundance of Hypoxanthine] affects the reaction [XDH protein affects the metabolism of Hypoxanthine]] which affects the abundance of Hydroxyl Radical affects abundance
/ affects metabolic processing
/ affects reaction
/ increases abundance
protein 7929072
D019271 7498 XDH
XO
XOR
xanthine dehydrogenase (EC:1.17.1.4 1.17.3.2) XDH protein affects the metabolism of Hypoxanthine affects metabolic processing
protein 7929072

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (2)

OMIM preferred title UniProt
#300323 Kelley-seegmiller syndrome P00492
#300322 Lesch-nyhan syndrome; lns P00492

KEGG DISEASE (1)

KEGG disease name UniProt
H00194 Lesch-Nyhan syndrome P00492 (related)

Diseases related to CTD interactions

3 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D019970 D019271 Cocaine-Related Disorders marker/mechanism
19649617
D005767 D019271 Gastrointestinal Diseases marker/mechanism
9199886
D011041 D019271 Poisoning marker/mechanism
22891888